FDA Approves Simparica Trio for Heartworm, Parasites in Dogs

Canine chewable fights heartworm disease, fleas and ticks, roundworm & hookworm

The U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA-CVM) announced March 2, 2020, that it has approved Simparica Trio (sarolaner, moxidectin and pyrantel) as a once-a-month treatment for dogs and puppies eight weeks of age and older, with the following indications:

  • Prevent heartworm disease caused by Dirofilaria immitis
  • Kill adult fleas, treat and prevent flea infestations
  • Treat and control tick infestations with the lone star tick, Gulf Coast tick, American dog tick, black-legged tick and brown dog tick
  • Treat and control roundworm and adult hookworm infections

FDA had previously approved each of the three main active ingredients for their separate indications, but is now approving Simparica Trio as a novel combination of these three antiparasitic drugs that combines each drug’s indications. Simparica Trio is available by prescription only. Because the product is indicated for the prevention of heartworm infection in dogs, prior to administering the product, a veterinary exam and blood test are necessary to ensure that a dog does not already have heartworm disease.

Zoetis Inc. of Kalamazoo, MI, is the sponsor of Simparica Trio.

Click here to read the full FDA announcement, including information about the three active ingredients in Simparica Trio, and possible side effects of the drug.